CIRC (01763) announced that its subsidiary, Atomic High-Tech Co., Ltd., has, for the first time, successfully achieved the domestic mass production of the radioactive isotope Germanium-68 using a 30MeV proton cyclotron. All quality indicators meet the stringent requirements for commercial nuclear products in Europe and America, marking a significant milestone as China now possesses independent and stable large-scale production capacity for Germanium-68, bringing hope for more precise diagnosis and treatment for cancer patients. Currently, only a handful of countries worldwide have mastered the technology for the mass production of Germanium-68.

Germanium-68 serves as the parent nuclide for the radioactive isotope Gallium-68, generating Gallium-68 through its decay process. Radiopharmaceuticals labeled with Gallium-68 are used in nuclear medicine for Positron Emission Tomography (PET) diagnostic imaging of tumors, providing critical data to support clinical diagnosis and treatment decisions. Presently, several Gallium-68-based drugs have been approved overseas for cancer diagnosis, while 13 such drugs have entered clinical trials within China.

With the increasing approval and widespread use of Gallium-68 drugs, the application prospects for Germanium-68 in both domestic and international markets are vast. Moving forward, Atomic High-Tech will continue to deepen its expertise in the field of nuclear medicine, focusing on the diagnostic and therapeutic needs for major diseases. The company plans to increase investment in the research and development of radiopharmaceuticals and technological innovation, aiming to support the advancement of precision medicine with higher-quality products and services, thereby building a more robust shield to safeguard public health.